The company is led by experienced biotech industry professionals and focuses on advancing its gene therapy programs for rare diseases, starting with hemophilia. They have a partnership with REGENX Biosciences, which gives them exclusive access to NAV vector technology and rights within REGENX product programs for multiple rare disease indications. Dimension has completed a Series A financing round led by Fidelity Biosciences.